Premier Alternatives

Angioinsight

Minnetonka, MN · Founded 2013 · Privately Held (backing)

Developer of artificial intelligence (AI) diagnostic tools designed to improve the detection and management of cardiovascular disease. Angioinsight is based in Minnetonka, MN and was founded in 2013. It is valued at about $18 million as of Oct 2026, set by institutional fund marks. It has raised $10.5 million.

PMV mark · valuation
$18.0M
Oct 2026
Priced at
—
Total raised
$10.5M
Last round
—

Angioinsight key facts

as of Oct 2026
  • Developer of artificial intelligence (AI) diagnostic tools designed to improve the detection and management of cardiovascular disease.
  • Angioinsight is valued at approximately $18.0M as of Oct 2026, per PrivateMarketView’s mark.
  • It has raised $10.5M; the latest was Later Stage VC ($25.0M) in Jul 2025.
  • Notable investors include US National Science Foundation, Innovation Partnerships, Avestria Ventures, Dakota Venture Group, Joyce and Don Massey Family Foundation — 6 tracked in total.
  • 1 institutional filer reports fund marks on Angioinsight across 6 filings.
  • Status: Privately Held (backing).
PrivateMarketView mark
LOW confidence
$18.0M

Reported valuation; nothing comparable since.

set by institutional fund marksas of Oct 2026question about this number?
Free account
More of Angioinsight with a free account
  • ·Watch Angioinsight: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Institutional fund marks on Angioinsight

1 filers · latest Jul 2026

1 SEC-registered fund reported 6 fair-value marks on Angioinsight between Apr 2025 and Jul 2026. Filer-level marks and implied $/share are available to Pro members.

Unlock 6 fund marks

Membership and data by Private Market View

Every name the funds mark, next to where it trades →

Angioinsight funding rounds

No rounds on record

No funding rounds for Angioinsight are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

Angioinsight valuation

Angioinsight is valued at approximately $18 million as of Oct 2026. The figure is set by institutional fund marks.

Recent activity

In the last 90 days, Angioinsight's record added 1 institutional fund mark (latest period Jul 2026).

Institutional holders and vehicles

1 SEC-registered fund reported 6 fair-value marks on Angioinsight between Apr 2025 and Jul 2026, in their N-PORT filings. Filer-level marks and implied per-share values are available to Pro members.

Angioinsight investors

6 investors are on record for Angioinsight, including US National Science Foundation, Innovation Partnerships, Avestria Ventures and Dakota Venture Group.

About Angioinsight

Developer of artificial intelligence (AI) diagnostic tools designed to improve the detection and management of cardiovascular disease. The company's platform delivers real-time, image-based assessments of both anatomical and functional conditions, including coronary microvascular disease, enabling more accurate, efficient, and accessible care for patients and providers.

Sector
Healthcare
HQ
Minnetonka, MN, United States
Founded
2013
Ownership
Privately Held (backing)

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.